Xtandi vs Pomalyst
Side-by-side drug price comparison from Medicare Part D data
Verdict
Xtandi costs 46% less per claim than Pomalyst ($9331.00 vs $17250.00). Xtandi has a generic alternative available. Total Medicare spending: Xtandi at $4.1B vs Pomalyst at $3.3B.
| Metric | Xtandi | Pomalyst |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $9,331* | $17,250 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $4.1B | $3.3B |
| Total Claims | 438,000 | 192,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 9.4% | 4.7%* |
| Generic Available | Yes | No |
| Condition | Cancer | Cancer |
| Total Beneficiaries | 46,000 | 18,000 |
Xtandi costs 46% less per claim than Pomalyst ($9331.00 vs $17250.00). Xtandi has a generic alternative available. Total Medicare spending: Xtandi at $4.1B vs Pomalyst at $3.3B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both entity A and entity B. What follows is the interpretation — which specific axes carry the most weight for entity A versus entity B, and which differences are large enough to influence a real decision.
Practical use of the comparison: read the data above, then drill into the individual entity A and entity B detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: CMS Medicare Part D Spending, 2026.